Literature DB >> 4061676

Pressor action and dipsogenicity induced by angiotensin II and III in rats.

J W Wright, S L Morseth, R H Abhold, J W Harding.   

Abstract

The primary brain sites responsible for angiotensin-induced pressor action and dipsogenicity in the laboratory rat appear to be located in forebrain circumventricular organs (CVO). Because CVOs have a reduced blood-brain barrier, intracarotid infusion of angiotensin via a brachial arterial catheter results in direct stimulation of these sites. This investigation determined that brachial arterial infusion of angiotensin II (ANG II) into alert free-moving rats resulted in pressor and dipsogenic responses greater than those observed with equivalent doses of angiotensin III (ANG III). However, intracerebroventricular (ICV) injections of ANG II and ANG III yielded equivalent pressor and drinking responses. ICV pretreatment with the specific angiotensin receptor antagonist [Sar1, Ile8]-ANG II significantly reduced ANG II- and ANG III-induced pressor and drinking responses. This inhibition lasted approximately 20 min with recovery at 60-70 min. The results indicate that ICV-administered ANG III is a much more potent ligand than previously determined if the stickiness due to electrical charge of this compound is prevented by appropriate treatment of glassware. The receptor antagonist results encourage the possibility that ANG II and ANG III activate a common central receptor site.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4061676     DOI: 10.1152/ajpregu.1985.249.5.R514

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  13 in total

1.  Contributions of the brain angiotensin IV-AT4 receptor subtype system to spatial learning.

Authors:  J W Wright; L Stubley; E S Pederson; E A Kramár; J M Hanesworth; J W Harding
Journal:  J Neurosci       Date:  1999-05-15       Impact factor: 6.167

Review 2.  The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases.

Authors:  John W Wright; Joseph W Harding
Journal:  Pflugers Arch       Date:  2012-04-26       Impact factor: 3.657

Review 3.  Orally Active Aminopeptidase A Inhibitor Prodrugs: Current State and Future Directions.

Authors:  Mathilde Keck; Reda Hmazzou; Catherine Llorens-Cortes
Journal:  Curr Hypertens Rep       Date:  2019-05-21       Impact factor: 5.369

4.  Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release.

Authors:  S Zini; M C Fournie-Zaluski; E Chauvel; B P Roques; P Corvol; C Llorens-Cortes
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

5.  Aminopeptidase A inhibitors as potential central antihypertensive agents.

Authors:  A Reaux; M C Fournie-Zaluski; C David; S Zini; B P Roques; P Corvol; C Llorens-Cortes
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

6.  Oxytocin changes primate paternal tolerance to offspring in food transfer.

Authors:  Atsuko Saito; Katsuki Nakamura
Journal:  J Comp Physiol A Neuroethol Sens Neural Behav Physiol       Date:  2011-01-12       Impact factor: 1.836

7.  Investigation into the specificity of angiotensin II-induced behavioral desensitization.

Authors:  Peter J Vento; Kevin P Myers; Derek Daniels
Journal:  Physiol Behav       Date:  2011-12-13

Review 8.  Role of angiotensin III in hypertension.

Authors:  Annabelle Reaux-Le Goazigo; Xavier Iturrioz; Celine Fassot; Cedric Claperon; Bernard P Roques; Catherine Llorens-Cortes
Journal:  Curr Hypertens Rep       Date:  2005-04       Impact factor: 5.369

Review 9.  Angiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets.

Authors:  John W Wright; Brent J Yamamoto; Joseph W Harding
Journal:  Prog Neurobiol       Date:  2007-11-19       Impact factor: 11.685

Review 10.  Aminopeptidase A inhibitors as centrally acting antihypertensive agents.

Authors:  Laurence Bodineau; Alain Frugière; Yannick Marc; Cédric Claperon; Catherine Llorens-Cortes
Journal:  Heart Fail Rev       Date:  2008-01-03       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.